Alumis (ALMS) Cash & Equivalents Growth (3y) (2026)
Powered by 
Analysis
Alumis (ALMS) Cash & Equivalents Growth (3y) (2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -23.18% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 14.34% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 37.45% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -27.97% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -3.85% |
| 10 | Alumis | 1.43 Bn | 923.47 Mn | - | -7.14% |